This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bank, A. J Articles by Billups, K. L Search for Related Content PubMed PubMed Citation Articles by Bank, A. J Articles by Billups, K. L Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATORVASTATIN HEPTANOIC ACID PYRROLE QUINAPRIL HYDROCHLORIDE Medline Plus Health Information Erectile Dysfunction Statins Social Bookmarking                   What's this?

The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction

St Paul Heart Clinic, 225 North Smith Avenue, Suite 400, St Paul, MN 55102, USA. Tel: +1 651 726 6767; Fax: +1 651 379 4457; abank{at}stphc.com; University of Minnesota, Minneapolis, MN, USA

Aaron S Kelly

Daniel R Kaiser

St Paul Heart Clinic, St Paul, MN, USA; University of Minnesota, Minneapolis, MN, USA

William W Crawford

St Paul Heart Clinic, St Paul, MN, USA

Benjamin Waxman

Metro Urology, St Paul, MN, USA

Douglas A Schow

The Minnesota Men's Health Center, Woodbury, MN, USA

Kevin L Billups

University of Minnesota, Minneapolis, MN, USA; The EpiCenter for Sexual Health and Medicine, Edina, MN, USA

Phosphodiesterase-5 (PDE-5) inhibitors are an effective therapy for the majority of men with erectile dysfunction (ED). However, many men with ED still report a suboptimal or partial response even after an adequate trial of oral PDE-5 therapy. Since ED is associated with impaired vascular function and both atorvastatin and quinapril have been previously shown to improve vascular function, we examined the effects of adjunctive treatment with these medications in men with vasculogenic ED who were suboptimal responders to 100 mg of sildenafil. Men with ED and suboptimal response to sildenafil were randomly assigned to 3 months of treatment with atorvastatin 40 mg (n = 12), quinapril 10 mg (n = 10), or placebo (n = 13), along with continued adjunctive sildenafil use. Measured variables included: International Index of Erectile Function (IIEF) questionnaire, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID) via nitroglycerin, penile Doppler blood flow, blood pressure (BP), lipids, and C-reactive protein (CRP). Compared to placebo, quinapril (p < 0.01) significantly improved symptoms of ED as measured by the IIEF-5 questionnaire. There was a trend toward a significant improvement in IIEF-5 with atorvastatin. Similarly, quinapril significantly improved the IIEF ED Domain (p < 0.05). Other peripheral and penile vascular parameters were unchanged with drug therapy as compared to placebo. In conclusion, treatment with quinapril, in combination with sildenafil, improved ED in men with suboptimal response to sildenafil alone. Atorvastatin demonstrated a trend toward improved ED in this group.

Key Words: atorvastatin • erectile dysfunction • quinapril

Vascular Medicine, Vol. 11, No. 4, 251-257 (2006)
DOI: 10.1177/1358863x06072221


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?